COVINGTON & BURLING LLP for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and intellectual property policy issues; Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); induced infringement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTA CARVER | — |
| NATALIE DERZKO | — |
| ANDREW DAVID LAZEROW | — |
| JENNIFER L PLITSCH | — |
| MICHAEL STERN | — |
Health Issues HCR
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTA CARVER | — |
| NATALIE DERZKO | — |
| RICHARD F KINGHAM | — |
| ANDREW DAVID LAZEROW | — |
| JENNIFER L PLITSCH | — |
| MICHAEL STERN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.